Seven tumours carried both KRAS and PIK3CA mutations, whereas BRAF mutations did not co-occur with the others; these frequencies closely match those in published reports (Wood et al, 2007) and were similar between the US and Greek cohorts (Supplementary Table 2). The gene discussed is KRAS; the disease is neoplasm.